Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Date:5/27/2009

-Clinical study planned for relapsed / refractory acute myelogenous leukemia-

PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1338, for the treatment of patients with acute myelogenous leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a chemokine receptor found on the surface of many cancer cells, including certain leukemias, lymphomas and other cancers. Preclinical laboratory experiments have shown that MDX-1338 can block the growth of, and even directly kill, selected human tumor cells.

The Phase 1, open-label, multicenter, dose-escalation study of MDX-1338 as a monotherapy and in combination with chemotherapy is expected to enroll up to 34 patients with relapsed/ refractory AML. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary pharmacodynamics and efficacy of MDX-1338.

"We are pleased that MDX-1338 has progressed into the clinic, representing our eighth development candidate in oncology and further enhancing our focus on oncology/immunology therapeutic indications," said Howard H. Pien, Chairman and CEO of Medarex. "We believe that MDX-1338 could have potential activity in multiple cancers. Our first Phase 1 study will be conducted in AML and future studies are expected to target a variety of other leukemias and solid tumors and may involve monotherapy and combination therapy."

The American Cancer Society estimates that in 2008, approximately 13,290 patients in the United States will be diagnosed with AML.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, developm
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
2. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
3. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
4. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
5. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
6. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
7. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
8. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
9. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 8, 2011 Reportlinker.com announces that a new ... Global Sepsis Therapeutics Industry ... This report analyzes the worldwide markets for ... sales of drugs used in the direct treatment ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) ... (DAA) currently in Phase IIb development for hepatitis C, ... Most Interesting Infectious Disease Projects to Watch. ... Top 10 infectious disease project," said Kevin Eastwood, Anadys, ...
Cached Medicine Technology:Global Sepsis Therapeutics Industry 2Global Sepsis Therapeutics Industry 3Global Sepsis Therapeutics Industry 4Global Sepsis Therapeutics Industry 5Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch 2Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch 3Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch 4
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... and alleviates muscle soreness after exercise, according to ... Illinois at Chicago. , The study, reported online ... of Physical Medicine and Rehabilitation , also showed ... had not exercised, suggesting that massage has benefits ... activity. , Improved circulation and relief of muscle ...
(Date:4/17/2014)... cent of Canadians surveyed said they would participate in ... number of genetic conditions, only 80 per cent said ... would sequence their newborns, genomes.,Most newborns in North America ... or two of life in which a tiny amount ... for about five to 54 conditions, depending on the ...
(Date:4/17/2014)... status as the leading weapon against the deadly disease ... new research indicating it simply needs to be administered ... the cheap anti-malarial drug chloroquine in treating and preventing ... than half a million people each year around the ... resistance to chloroquine, but research carried out at the ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... blocks muscle growth, has shown promising results as a ... studies, where its inhibition led to increased muscle mass ... a myostatin inhibitor in patients, assessed its safety in ... well-tolerated. The study was published today in Annals of ...
... in Boone County to house world class research, center in country,s ... of personalized medicine into mainstream ... ... MHS ), joined by Indiana Gov. Mitch Daniels, broke,ground today on its ...
... Holdings Corp.,(Nasdaq: HMSY ) today announced that it ... which will be held March 26-27, 2008 at the ... of HMS Holdings Corp., will,present on Wednesday, March 26th ... HMSY ) is a national leader in cost,containment ...
... hospitals will aggravate existing problems, ... ... state legislators to reject a proposal to,eliminate the state,s planning process for ... huge cuts in,funding to care for the elderly and poor, and already ...
... recurrent or new tumors by more than half, study found ... good news for the 60 percent of women with breast ... inhibitor (AI) drug letrozole (Femara) can cut risk of a ... even when women initiated the drug one to seven years ...
... &,Johnson will participate in the Eleventh Annual Lehman ... the Loews Miami Beach Hotel,in Miami, Florida. Dominic ... represent the Company in a session scheduled at,11:15 ... available to investors and other interested parties,by accessing ...
Cached Medicine News:Health News:New potential treatment for muscular dystrophy appears to be safe 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 3Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 4Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 5Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 2Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 3Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: